All the news Showing 10 of 30 articles from: GermanyGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources NAFLD People with HIV taking newer antiretrovirals at higher risk of fatty liver disease Keith Alcorn / 08 October 2021 People with HIV were more likely to develop fatty liver disease if they took antiretroviral treatment that contains an integrase inhibitor or tenofovir alafenamide (TAF), a German research group has found. Non-alcoholic ... Hepatitis D Bulevirtide appears safe and effective for hepatitis D Liz Highleyman / 28 June 2021 The entry inhibitor bulevirtide (Hepcludex) suppressed hepatitis delta viral load and improved liver enzyme levels in a phase III clinical trial, according to late-breaking study results presented this week at the 2021 International Liver ... Coronavirus Hepatitis C Drugs May Help Fight COVID-19, Suggests Study NDTV / 07 May 2020 Hepatitis delta Combination therapies show promise against hepatitis D Liz Highleyman / 16 December 2019 Combination regimens using lonafarnib or bulevirtide reduced levels of hepatitis delta virus (HDV) in a majority of people with HDV and hepatitis B virus (HBV) co-infection, researchers reported at the AASLD Liver Meeting ... Hepatitis D Bulevirtide is a potential cure for hepatitis B and D Liz Highleyman / 16 April 2019 Bulevirtide, formerly known as Myrcludex B, led to suppression of hepatitis delta virus (HDV) and a functional cure of hepatitis B virus (HBV) in some people with both viruses when combined with pegylated ... Pan-genotypic regimens Pangenotypic hepatitis C drug combinations curing almost all people who complete treatment, real-world studies show Keith Alcorn / 12 April 2019 Once-daily combination pills that can treat all genotypes of hepatitis C infection are curing almost everyone who completes a course of treatment, and drop-out rates during treatment are low, large 'real-world' cohort ... Cirrhosis Hepatitis: Liver failure attributable to compromised blood supply Eurekalert / 16 January 2019 Treatment issues DAAs safe and effective in elderly people with HCV Michael Carter / 05 September 2018 Treatment with direct-acting antivirals (DAAs) is safe and effective in elderly people with hepatitis C virus (HCV) infection, according to German research published in Drugs & Aging. Elderly people (aged 70 years ... Hepatitis D Myrcludex B plus tenofovir suppresses hepatitis delta Liz Highleyman / 30 April 2018 An experimental drug that blocks the entry of hepatitis B virus (HBV) and hepatitis delta virus (HDV) into liver cells suppressed HBV and HDV levels and led to improvement in ... NAFLD Costs Balloon after Cirrhosis Diagnosis for NAFLD/NASH MedPage Today Gastroenterology / 17 April 2018 ← First123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive